Skip to main content

Month: June 2024

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th Scientific Session BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, and Dr. Timothy Kieffer, CSO of Fractyl Health, will participate in a virtual fireside chat at the upcoming Piper Sandler 2nd Annual Virtual Obesity Day on Wednesday, June 26, 2024 at 9:30 a.m. EDT. The Company will discuss the acceleration of its weight maintenance clinical study, which it recently announced, as well...

Continue reading

Skye BioScience Participating in Piper Sandler Virtual Obesity Day

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will participate in the Piper Sandler Virtual Obesity Day with ADA 2024 Conference Takeaways on Wednesday, June 26, 2024. The event includes presentations by KOLs and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event through their representative. Skye Bioscience Fireside Chat11:30-11:55 a.m. ETSkye Participants:Punit Dhillon, CEO & Chair Tu Diep, MSc, Chief Development Officer Chris Twitty, PhD, Chief Scientific OfficerAbout Skye Bioscience...

Continue reading

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatment Results supportive of Phase 3 SERENITY and TRANQUILITY programs NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive topline results from a post-marketing requirement (PMR) study of IGALMI™ (dexmedetomidine) sublingual film that demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose after seven days of PRN...

Continue reading

West Red Lake Gold Strengthens Management Team

VANCOUVER, British Columbia, June 25, 2024 (GLOBE NEWSWIRE) — West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF) is pleased to announce the appointment of Jason Billan as Vice President Corporate Development effective June 24, 2024. Mr. Billan has spent 15 years in the mining sector, with an emphasis on corporate development, strategy, financing, and executive leadership. Following an MBA at the University of Western Ontario in 2009, he spent three years in precious metals equity research at Salman Partners and RBC Capital Markets, with a coverage universe ranging from small exploration companies to large producers. In 2012, he joined Nevsun Resources as a corporate development analyst. In 2016 Nevsun acquired the Timok copper-gold project in Serbia for over US$500M before...

Continue reading

First Atlantic Nickel Identifies 30km Awaruite Nickel Trend From Data Compilation at its Atlantic Nickel Project in Central Newfoundland

VANCOUVER, British Columbia, June 25, 2024 (GLOBE NEWSWIRE) — First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or “FAN” or the “Company”) is pleased to announce it has completed a large-scale data compilation for its 21,850-hectare Atlantic Nickel Project in Central Newfoundland, Canada. This first-time extensive review, covering the entire Pipestone Ophiolite Ultramafic Complex, identified over 700 regional exploration reports. Of these, 134 contained relevant project information, including data on prospecting, geological mapping, airborne geophysics, geochemistry, and drilling. The data compilation program outlined a 30-km core trend with consistent, highly anomalous nickel concentrations, strongly correlating with the Pipestone Complex’s high-magnetic ultramafic rocks. These rocks have...

Continue reading

Robinson Capital Announces Quarterly Distributions on $SPAX

GROSSE POINTE FARMS, Mich., June 25, 2024 (GLOBE NEWSWIRE) — Robinson Capital today announced quarterly distributions on the Robinson Alternative Yield Pre-Merger SPAC ETF (SPAX). Distribution as of 06/25/2024ETFTicker Distributionper Share Ex-Date RecordDate PaymentDateSPAX $0.27 06/26/2024 06/26/2024 06/28/2024SPAX, launched in partnership with Tidal Investments LLC, is an actively managed exchange-traded fund (ETF) that invests primarily in pre-merger Special Purpose Acquisition Companies (SPACs), which offer the potential for mitigating downside risk and capturing upside opportunity. SPAX seeks to provide total return while minimizing downside risk. About Robinson CapitalFounded in 2012, Robinson Capital Management is an independent investment advisor specialized in developing both traditional and alternative fixed...

Continue reading

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company’s US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. “We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy,” said Kevin Hykes, President and CEO of CVRx. “Robert is well-known and respected within the heart failure community and has extensive experience building global sales organizations, launching novel heart failure therapies, and...

Continue reading

TransUnion Announces Earnings Release Date for Second Quarter 2024 Results

CHICAGO, June 25, 2024 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) will publish its financial results for the second quarter ended June 30, 2024, in a press release to be issued at approximately 6:00 a.m. Central Time (CT) on Thursday, July 25, 2024. The company will hold a conference call on the same day at 8:30 a.m. Central Time (CT) to discuss its financial results. The press release and a live webcast of the earnings conference call will be available on the TransUnion Investor Relations website at http://www.transunion.com/tru. About TransUnion (NYSE: TRU) TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable...

Continue reading

First Quantum Provides Notice of Second Quarter 2024 Results

TORONTO, June 25, 2024 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) will release second quarter 2024 financial and operating results on Tuesday, July 23, 2024 after the close of the Toronto Stock Exchange. The Company will host a conference call and webcast to discuss the results on Wednesday, July 24, 2024 at 9:00 am (ET). Conference call and webcast details:Toll-free North America: 1-844-763-8274Toll-free International: +1-647-484-8814Webcast: Direct link or on our website A replay of the webcast will be available on the First Quantum website. For further information, visit our website at www.first-quantum.com or contact: Bonita To, Director, Investor Relations (416) 361-6400 Toll-free: 1 (888) 688-6577E-Mail: info@fqml.com

Continue reading

Azimut Announces Discovery of Spodumene Pegmatites at Pilipas, James Bay Region, Quebec

LONGUEUIL, Québec, June 25, 2024 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to report the discovery of spodumene bearing pegmatite outcrops on the Pilipas Property (the “Property”) in the Eeyou Istchee James Bay region of Quebec, Canada (Figure 1). Ophir Metals Corp. (formerly Ophir Gold Corp.) (“Ophir”) (TSXV: OPHR) (OTCQB: OPHRF), as operator under the option agreement, is completing an inaugural lithium-focused surface exploration program on the Property (see press releases of December 11, 2023 and May 14, 2024). HIGHLIGHTS (see Figure 2)A spodumene bearing pegmatite occurrence was discovered on the Property at the Highway showing (“HW1”). This spodumene pegmatite is open in multiple directions with an approximate strike length of over 150 m and width of up...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.